Veracyte股价上涨,因数据支持将前列腺癌检测用于指导治疗决策

路透中文
Sep 29
BUZZ-Veracyte股价上涨,因数据支持将前列腺癌检测用于指导治疗决策

9月29日 - ** 诊断公司Veracyte(VCYT.O)的股价在盘前交易中上涨1.6%,至45.94美元

** 该公司表示,其Decipher检测能够识别出最有可能从放疗联合激素治疗中获益的中危前列腺癌患者

** 前列腺癌是发生在前列腺的癌症;激素疗法可降低促进肿瘤生长的激素水平

** Veracyte表示,对于Decipher评分处于中/高水平的患者,在联合应用激素治疗后,10年内的癌症扩散率降低了8个百分点

** 约44%的患者评分较低,在联合激素治疗后未见显著获益

** 该研究结果基于一项针对晚期前列腺癌临床试验中395名患者的回顾性分析

** 截至上一交易日收盘,该股年内累计跌幅约为23%

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10